1098 related articles for article (PubMed ID: 33143537)
21. Discovery of E3 Ligase Ligands for Target Protein Degradation.
Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
[TBL] [Abstract][Full Text] [Related]
22. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
[TBL] [Abstract][Full Text] [Related]
23. Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs.
Anderson NA; Cryan J; Ahmed A; Dai H; McGonagle GA; Rozier C; Benowitz AB
Bioorg Med Chem Lett; 2020 May; 30(9):127106. PubMed ID: 32184044
[TBL] [Abstract][Full Text] [Related]
24. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
25. A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation.
Wurz RP; Dellamaggiore K; Dou H; Javier N; Lo MC; McCarter JD; Mohl D; Sastri C; Lipford JR; Cee VJ
J Med Chem; 2018 Jan; 61(2):453-461. PubMed ID: 28378579
[TBL] [Abstract][Full Text] [Related]
26. A beginner's guide to current synthetic linker strategies towards VHL-recruiting PROTACs.
Zografou-Barredo NA; Hallatt AJ; Goujon-Ricci J; Cano C
Bioorg Med Chem; 2023 Jun; 88-89():117334. PubMed ID: 37224698
[TBL] [Abstract][Full Text] [Related]
27. The Vital Role of Proteomics in Characterizing Novel Protein Degraders.
Zhang AX; Cassidy K; Dahl G; Moreau K; Pachl F; Zuhl AM
SLAS Discov; 2021 Apr; 26(4):518-523. PubMed ID: 33615886
[TBL] [Abstract][Full Text] [Related]
28. New strategy for renal fibrosis: Targeting Smad3 proteins for ubiquitination and degradation.
Wang X; Feng S; Fan J; Li X; Wen Q; Luo N
Biochem Pharmacol; 2016 Sep; 116():200-9. PubMed ID: 27473774
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and Evaluation of Cereblon-Recruiting HaloPROTACs.
Ody BK; Zhang J; Nelson SE; Xie Y; Liu R; Dodd CJ; Jacobs SE; Whitzel SL; Williams LA; Gozem S; Turlington M; Yin J
Chembiochem; 2023 Nov; 24(21):e202300498. PubMed ID: 37625128
[TBL] [Abstract][Full Text] [Related]
30. A Cell-Based Target Engagement Assay for the Identification of Cereblon E3Â Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.
Yang K; Zhao Y; Nie X; Wu H; Wang B; Almodovar-Rivera CM; Xie H; Tang W
Cell Chem Biol; 2020 Jul; 27(7):866-876.e8. PubMed ID: 32413286
[TBL] [Abstract][Full Text] [Related]
31. Ligandability of E3 Ligases for Targeted Protein Degradation Applications.
Belcher BP; Ward CC; Nomura DK
Biochemistry; 2023 Feb; 62(3):588-600. PubMed ID: 34473924
[TBL] [Abstract][Full Text] [Related]
32. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
Han X; Zhao L; Xiang W; Qin C; Miao B; Xu T; Wang M; Yang CY; Chinnaswamy K; Stuckey J; Wang S
J Med Chem; 2019 Dec; 62(24):11218-11231. PubMed ID: 31804827
[TBL] [Abstract][Full Text] [Related]
33. E3 ligase ligand optimization of Clinical PROTACs.
Jiang H; Xiong H; Gu SX; Wang M
Front Chem; 2023; 11():1098331. PubMed ID: 36733714
[TBL] [Abstract][Full Text] [Related]
34. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera.
Kim K; Lee DH; Park S; Jo SH; Ku B; Park SG; Park BC; Jeon YU; Ahn S; Kang CH; Hwang D; Chae S; Ha JD; Kim S; Hwang JY; Kim JH
Sci Rep; 2019 Dec; 9(1):19654. PubMed ID: 31873151
[TBL] [Abstract][Full Text] [Related]
35. Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells.
Mahan SD; Riching KM; Urh M; Daniels DL
Methods Mol Biol; 2021; 2365():151-171. PubMed ID: 34432243
[TBL] [Abstract][Full Text] [Related]
36. Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes.
Zhang L; Riley-Gillis B; Vijay P; Shen Y
Mol Cancer Ther; 2019 Jul; 18(7):1302-1311. PubMed ID: 31064868
[TBL] [Abstract][Full Text] [Related]
37. Exploiting the Cullin E3 Ligase Adaptor Protein SKP1 for Targeted Protein Degradation.
Hong SH; Divakaran A; Osa A; Huang OW; Wertz IE; Nomura DK
ACS Chem Biol; 2024 Feb; 19(2):442-450. PubMed ID: 38305738
[TBL] [Abstract][Full Text] [Related]
38. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
[TBL] [Abstract][Full Text] [Related]
39. Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders.
Hu J; Wei J; Yim H; Wang L; Xie L; Jin MS; Kabir M; Qin L; Chen X; Liu J; Jin J
J Med Chem; 2020 Dec; 63(24):15883-15905. PubMed ID: 33284613
[TBL] [Abstract][Full Text] [Related]
40. Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands.
Xu H; Kurohara T; Ohoka N; Tsuji G; Inoue T; Naito M; Demizu Y
Bioorg Med Chem; 2023 May; 86():117293. PubMed ID: 37126968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
